CL2021000184A1 - Piridopirimidinas como inhibidores del receptor de histamina h4 - Google Patents

Piridopirimidinas como inhibidores del receptor de histamina h4

Info

Publication number
CL2021000184A1
CL2021000184A1 CL2021000184A CL2021000184A CL2021000184A1 CL 2021000184 A1 CL2021000184 A1 CL 2021000184A1 CL 2021000184 A CL2021000184 A CL 2021000184A CL 2021000184 A CL2021000184 A CL 2021000184A CL 2021000184 A1 CL2021000184 A1 CL 2021000184A1
Authority
CL
Chile
Prior art keywords
histamine
pyridopyrimidines
receptor inhibitors
receptor
solvates
Prior art date
Application number
CL2021000184A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernández
Tizne Roberto Olivera
Arce Arturo Zazpe
Cerdeiras Paloma Tato
Domínguez Neftalí García
Pedro Bárbara Noverges
Vivar Reyes Corcóstegui
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of CL2021000184A1 publication Critical patent/CL2021000184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula (I): (I) o a sales o solvatos farmacéuticamente aceptables de los mismos, a composiciones farmacéuticas que los comprenden y a su uso en el tratamiento y/o la prevención de enfermedades o trastornos mediados por el receptor de histamina H4.
CL2021000184A 2018-07-25 2021-01-22 Piridopirimidinas como inhibidores del receptor de histamina h4 CL2021000184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382559 2018-07-25

Publications (1)

Publication Number Publication Date
CL2021000184A1 true CL2021000184A1 (es) 2021-07-09

Family

ID=63207688

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000184A CL2021000184A1 (es) 2018-07-25 2021-01-22 Piridopirimidinas como inhibidores del receptor de histamina h4

Country Status (29)

Country Link
US (1) US12492199B2 (es)
EP (1) EP3827005B1 (es)
JP (1) JP7093462B2 (es)
KR (1) KR102603203B1 (es)
CN (1) CN112739699B (es)
AU (1) AU2019310889B2 (es)
BR (1) BR112021001270A2 (es)
CA (1) CA3107556C (es)
CL (1) CL2021000184A1 (es)
CO (1) CO2021001925A2 (es)
DK (1) DK3827005T3 (es)
EA (1) EA202190339A1 (es)
EC (1) ECSP21010874A (es)
ES (1) ES2929227T3 (es)
HR (1) HRP20221250T1 (es)
HU (1) HUE059824T2 (es)
LT (1) LT3827005T (es)
MA (1) MA53372B1 (es)
MX (1) MX2021000966A (es)
MY (1) MY206632A (es)
PE (1) PE20211638A1 (es)
PH (1) PH12021550143A1 (es)
PL (1) PL3827005T3 (es)
PT (1) PT3827005T (es)
RS (1) RS63661B1 (es)
SA (1) SA521421098B1 (es)
SG (1) SG11202100575QA (es)
WO (1) WO2020020939A1 (es)
ZA (1) ZA202101092B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014116A (es) * 2019-05-31 2021-12-10 Chiesi Farm Spa Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
JP2023084709A (ja) * 2020-04-28 2023-06-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ヒスタミンｈ４受容体調節作用を有する新規二環化合物
WO2026062171A1 (en) 2024-09-20 2026-03-26 Faes Farma, S.A. Pyridopyrimidine derivative as histamine receptor inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002434A (es) 2004-08-31 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
RU2011116928A (ru) * 2008-09-30 2012-11-20 Астразенека Аб (Se) Гетероциклические ингибиторы jак киназы
US8481732B2 (en) 2009-03-20 2013-07-09 Incyte Corporation Substituted heterocyclic compounds
EP2270002A1 (en) 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
WO2013060881A1 (en) 2011-10-27 2013-05-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Pyridopyrimidines and their therapeutic use
EA030253B1 (ru) * 2012-09-28 2018-07-31 Кэнсэр Ресерч Текнолоджи Лимитед Азахиназолиновые ингибиторы атипичной протеинкиназы c
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents
WO2018190778A1 (en) 2017-04-12 2018-10-18 Thammasat University Inspection procedure of the authenticity of brand-named leather bag

Also Published As

Publication number Publication date
US12492199B2 (en) 2025-12-09
KR20210038909A (ko) 2021-04-08
WO2020020939A1 (en) 2020-01-30
ES2929227T3 (es) 2022-11-25
EP3827005A1 (en) 2021-06-02
BR112021001270A2 (pt) 2021-04-20
SA521421098B1 (ar) 2024-02-08
MA53372B1 (fr) 2022-10-31
PE20211638A1 (es) 2021-08-24
RS63661B1 (sr) 2022-11-30
CA3107556A1 (en) 2020-01-30
EA202190339A1 (ru) 2021-05-20
JP2021531304A (ja) 2021-11-18
US20210300922A1 (en) 2021-09-30
MA53372A (fr) 2021-06-02
SG11202100575QA (en) 2021-02-25
EP3827005B1 (en) 2022-08-17
PH12021550143A1 (en) 2021-09-13
PL3827005T3 (pl) 2022-11-28
HRP20221250T1 (hr) 2022-12-09
CO2021001925A2 (es) 2021-03-08
NZ773053A (en) 2023-10-27
CN112739699B (zh) 2023-11-28
JP7093462B2 (ja) 2022-06-29
MY206632A (en) 2024-12-27
AU2019310889A1 (en) 2021-03-11
PT3827005T (pt) 2022-11-04
AU2019310889B2 (en) 2022-03-31
CA3107556C (en) 2022-10-25
CN112739699A (zh) 2021-04-30
KR102603203B1 (ko) 2023-11-16
MX2021000966A (es) 2021-07-06
DK3827005T3 (da) 2022-09-19
LT3827005T (lt) 2022-11-10
ECSP21010874A (es) 2021-03-31
HUE059824T2 (hu) 2023-01-28
ZA202101092B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2019004685A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX2019010736A (es) Inhibidor del antigeno de superficie del virus de la hepatitis b.
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2021000329A1 (es) Compuestos útiles en terapia del vih
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
AR123685A1 (es) Antagonistas del mrgx2
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
CR20220299A (es) Derivados de becimidazol
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
MX2019010993A (es) Derivados de tetrahidroquinolina como antagonistas del receptor p2x7.